# Study to Assess the Efficacy and Safety of Eutropin in Prader-Willi Syndrome

> **NCT02204163** · PHASE3 · COMPLETED · sponsor: **LG Life Sciences** · enrollment: 34 (actual)

## Conditions studied

- Prader-Willi Syndrome

## Interventions

- **DRUG:** Eutropin
- **DRUG:** Genotropin

## Key facts

- **NCT ID:** NCT02204163
- **Lead sponsor:** LG Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2019-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02204163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02204163, "Study to Assess the Efficacy and Safety of Eutropin in Prader-Willi Syndrome". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02204163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*